Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Cost-Effectiveness Study.

Khan, Faizan; Coyle, Doug; Thavorn, Kednapa; van Katwyk, Sasha; Tritschler, Tobias; Hutton, Brian; Le Gal, Grégoire; Rodger, Marc A; Fergusson, Dean A (2023). Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Cost-Effectiveness Study. Annals of internal medicine, 176(7), pp. 949-960. American College of Physicians 10.7326/M22-3559

Text m22-3559.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (327kB)

BACKGROUND

Clinical practice guidelines recommend indefinite anticoagulation for a first unprovoked venous thromboembolism (VTE).

OBJECTIVE

To estimate the benefit-harm tradeoffs of indefinite anticoagulation in patients with a first unprovoked VTE.

DESIGN

Markov modeling study.

DATA SOURCES

Systematic reviews and meta-analyses for the long-term risks and case-fatality rates of recurrent VTE and major bleeding. Published literature for costs, quality of life, and other clinical events.

TARGET POPULATION

Patients with a first unprovoked VTE who have completed 3 to 6 months of initial anticoagulant treatment.

TIME HORIZON

Lifetime.

PERSPECTIVE

Canadian health care public payer.

INTERVENTION

Indefinite anticoagulation with direct oral anticoagulants.

OUTCOME MEASURES

Recurrent VTE events, major bleeding events, costs in 2022 Canadian dollars (CAD), and quality-adjusted life-years (QALYs).

RESULTS OF BASE-CASE ANALYSIS

When compared with discontinuing anticoagulation after initial treatment in a hypothetical cohort of 1000 patients aged 55 years, indefinite anticoagulation prevented 368 recurrent VTE events, which included 14 fatal pulmonary emboli, but induced an additional 114 major bleeding events, which included 30 intracranial hemorrhages and 11 deaths from bleeding. Indefinite anticoagulation cost CAD $16 014 more per person and did not increase QALYs (-0.075 per person).

RESULTS OF SENSITIVITY ANALYSIS

Model results were most sensitive to the case-fatality rate of major bleeding and the annual risk for major bleeding during extended anticoagulation.

LIMITATION

The model assumed that risks for recurrent VTE and major bleeding measured in clinical trials at 1 year remained constant during extended anticoagulation.

CONCLUSION

Clinicians should use shared decision making to incorporate individual patient preferences and values when considering treatment duration for unprovoked VTE.

PRIMARY FUNDING SOURCE

Canadian Institutes of Health Research.

Interest & Impact

Downloads

1 since deposited on 27 Jun 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item